サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1546231

タンパク質結合アッセイの世界市場

Protein Binding Assays

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
タンパク質結合アッセイの世界市場
出版日: 2024年09月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

タンパク質結合アッセイの世界市場は2030年までに8億3,490万米ドルに達する見込み

2023年に4億4,420万米ドルと推定されたタンパク質結合アッセイの世界市場は、2030年には8億3,490万米ドルに達し、分析期間2023-2030年のCAGRは9.4%で成長すると予測されます。本レポートで分析したセグメントの1つである平衡透析技術は、CAGR 9.6%を記録し、分析期間終了時には3億4,220万米ドルに達すると予測されます。限外ろ過技術セグメントの成長率は、分析期間中CAGR 9.8%と推定されます。

米国市場は1億2,090万米ドルと推定、中国はCAGR 8.7%で成長すると予測

米国のタンパク質結合アッセイ市場は、2023年に1億2,090万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 8.7%で推移し、2030年には1億2,770万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.2%と8.0%と予測されています。欧州では、ドイツがCAGR 7.3%で成長すると予測されています。

世界のタンパク質結合アッセイ市場- 主要動向と促進要因のまとめ

複雑さを理解する拡大するタンパク質結合アッセイ市場

タンパク質結合アッセイは、創薬や薬剤開発において重要なツールであり、薬剤と標的タンパク質との相互作用に関する重要な知見を提供します。これらのアッセイは、研究者が薬物の薬物動態、薬力学、および全体的な有効性を理解するために重要なタンパク質への結合親和性を決定するのに役立ちます。製薬業界やバイオテクノロジー業界は、潜在的な薬剤候補をスクリーニングし、リード化合物を最適化するために、薬剤開発の初期段階でこれらのアッセイに大きく依存しています。個別化医療の需要が高まるにつれ、タンパク質結合アッセイは特定の患者集団に合わせた薬剤の同定と開発にますます重要な役割を果たすようになり、現代のヘルスケアに欠かせないものとなっています。

技術の進歩はアッセイの精度と効率をどのように高めているのか？

技術の進歩は、タンパク質結合アッセイの精度、感度、効率を著しく向上させています。ハイスループットスクリーニング（HTS）技術の開発により、何千もの化合物の同時分析が可能になり、創薬プロセスが加速されました。さらに、表面プラズモン共鳴（SPR）や等温滴定カロリメトリー（ITC）のようなラベルフリーの検出法の革新は、蛍光ラベルや放射性ラベルを必要とせずに、結合相互作用をより正確に測定することを可能にしました。これらの進歩は、タンパク質結合アッセイによって生成されるデータの信頼性を向上させただけでなく、医薬品開発に関連する時間とコストを削減しました。さらに、人工知能（AI）と機械学習アルゴリズムの統合により、これらのアッセイの予測能力が強化され、潜在的な医薬品候補をより正確に同定できるようになっています。

規制遵守は市場でどのような役割を果たしているか？

規制遵守は、製薬およびバイオテクノロジー業界における先進的なタンパク質結合アッセイの採用を促進する重要な要因です。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、医薬品承認プロセスの一環として、薬物-タンパク質相互作用に関する包括的なデータを必要としています。このため、正確で再現性のある結果を提供し、医薬品の安全性と有効性を保証するアッセイに対する要求が高まっています。医薬品承認のための厳しい要件は、企業に最新のアッセイ技術と方法論の採用を促し、この分野の技術革新をさらに促進しています。さらに、タンパク質結合特性の詳細な特性評価を必要とするバイオシミラーや生物製剤への注目の高まりが、先進的なタンパク質結合アッセイへの需要をさらに高めています。

市場成長の主な促進要因は？

タンパク質結合アッセイ市場の成長は、いくつかの要因によってもたらされます。個別化医療や標的治療に対する需要の高まりが、より正確で信頼性の高いタンパク質結合アッセイの必要性に拍車をかけています。ハイスループット・スクリーニング技術やラベルフリー検出法の開発などの技術的進歩により、これらのアッセイの効率と精度が大幅に向上し、創薬や薬剤開発における採用が促進されています。また、医薬品とタンパク質の相互作用に関する包括的なデータに対する規制上の要件も、企業が厳格な安全性と有効性の基準への準拠を確保しようとする中で、市場の牽引役として重要な役割を果たしています。さらに、タンパク質の詳細な特性解析を必要とする生物製剤やバイオシミラーへの注目が高まっていることも、タンパク質結合アッセイの需要をさらに押し上げています。

調査対象企業の例（注目の44社）

  • Absorption Systems LLC
  • ADMEcell, Inc.
  • Biotium, Inc.
  • Danaher Corporation
  • Eurofins Scientific
  • GE Healthcare Life Sciences
  • HTDialysis, LLC
  • Merck & Co., Inc.
  • Sovicell GmbH
  • Thermo Fisher Scientific, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP14257

Global Protein Binding Assays Market to Reach US$834.9 Million by 2030

The global market for Protein Binding Assays estimated at US$444.2 Million in the year 2023, is expected to reach US$834.9 Million by 2030, growing at a CAGR of 9.4% over the analysis period 2023-2030. Equilibrium Dialysis Technology, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$342.2 Million by the end of the analysis period. Growth in the Ultrafiltration Technology segment is estimated at 9.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$120.9 Million While China is Forecast to Grow at 8.7% CAGR

The Protein Binding Assays market in the U.S. is estimated at US$120.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$127.7 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Global Protein Binding Assays Market - Key Trends and Drivers Summarized

Understanding the Complexities: The Expanding Market for Protein Binding Assays

Protein binding assays are crucial tools in drug discovery and development, providing essential insights into the interactions between drugs and their target proteins. These assays help researchers determine the binding affinity of a drug to a protein, which is critical for understanding its pharmacokinetics, pharmacodynamics, and overall efficacy. The pharmaceutical and biotechnology industries heavily rely on these assays during the early stages of drug development to screen potential drug candidates and optimize lead compounds. As the demand for personalized medicine grows, protein binding assays play an increasingly vital role in identifying and developing drugs tailored to specific patient populations, making them indispensable in modern healthcare.

How Are Technological Advancements Enhancing Assay Accuracy and Efficiency?

Technological advancements have significantly improved the accuracy, sensitivity, and efficiency of protein binding assays. The development of high-throughput screening (HTS) technologies has enabled the simultaneous analysis of thousands of compounds, accelerating the drug discovery process. Additionally, innovations in label-free detection methods, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), have provided more precise measurements of binding interactions without the need for fluorescent or radioactive labels. These advancements have not only improved the reliability of the data generated by protein binding assays but have also reduced the time and cost associated with drug development. Furthermore, the integration of artificial intelligence (AI) and machine learning algorithms is enhancing the predictive capabilities of these assays, allowing for more accurate identification of potential drug candidates.

What Role Does Regulatory Compliance Play in the Market?

Regulatory compliance is a significant factor driving the adoption of advanced protein binding assays in the pharmaceutical and biotechnology industries. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require comprehensive data on drug-protein interactions as part of the drug approval process. This has led to an increased demand for assays that provide accurate and reproducible results, ensuring that drugs are both safe and effective. The stringent requirements for drug approval have pushed companies to adopt the latest assay technologies and methodologies, further driving innovation in the field. Additionally, the growing focus on biosimilars and biologics, which require detailed characterization of protein binding properties, has further increased the demand for advanced protein binding assays.

What Are the Key Growth Drivers in the Market?

The growth in the protein binding assays market is driven by several factors. The increasing demand for personalized medicine and targeted therapies has spurred the need for more accurate and reliable protein binding assays. Technological advancements, such as the development of high-throughput screening technologies and label-free detection methods, have significantly improved the efficiency and accuracy of these assays, driving their adoption in drug discovery and development. Regulatory requirements for comprehensive data on drug-protein interactions have also played a crucial role in driving the market, as companies seek to ensure compliance with stringent safety and efficacy standards. Additionally, the growing focus on biologics and biosimilars, which require detailed protein characterization, is further propelling the demand for protein binding assays.

Select Competitors (Total 44 Featured) -

  • Absorption Systems LLC
  • ADMEcell, Inc.
  • Biotium, Inc.
  • Danaher Corporation
  • Eurofins Scientific
  • GE Healthcare Life Sciences
  • HTDialysis, LLC
  • Merck & Co., Inc.
  • Sovicell GmbH
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Protein Binding Assays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand in Drug Discovery and Development Propels Market Growth
    • Increasing Use in Pharmacokinetics Expands Addressable Market Opportunity
    • Technological Advancements in High-Throughput Screening Strengthen Market Position
    • Growing Focus on Personalized Medicine Drives Adoption of Protein Binding Assays
    • Surge in Demand for Accurate and Reliable Assay Technologies Generates New Opportunities
    • Development of Novel Assay Formats Sustains Market Growth
    • Expanding Applications in Toxicology Testing Throws Spotlight on Market Potential
    • Surge in Demand for Assays in Biologics Development Expands Market Horizons
    • Growing Awareness of Drug-Protein Interactions Drives Market Adoption
    • Innovations in Label-Free Detection Technologies Generate New Market Opportunities
    • Rising Use of Protein Binding Assays in Clinical research Throws Spotlight on Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Protein Binding Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Protein Binding Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Equilibrium Dialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Equilibrium Dialysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ultrafiltration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Ultrafiltration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Ultracentrifugation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Ultracentrifugation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Protein Binding Assays Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Research & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Research & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Canada 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Canada 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • JAPAN
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Japan 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • CHINA
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 30: China Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: China 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 32: China Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • EUROPE
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Protein Binding Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 35: Europe 7-Year Perspective for Protein Binding Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Europe 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • FRANCE
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 40: France Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: France 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 42: France Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: France 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • GERMANY
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Germany 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • ITALY
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Italy 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Italy 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • UNITED KINGDOM
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 52: UK Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: UK 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 54: UK Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: UK 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Rest of World 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of World 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030

IV. COMPETITION